Choosing the right chemotherapy regimen is one of the hardest calls in cancer care. The wrong combination can mean a treatment that fails to control the disease, or one that triggers severe side effects. A new systematic review is now examining whether artificial intelligence can help doctors make that choice better.
The review, published in the medical journal Cureus, is titled "AI-Assisted Chemotherapy Regimen Selection and Its Effects on Clinical Outcomes and Adverse Drug Reactions." As its title indicates, the paper looks specifically at two questions: whether AI-guided selection improves clinical outcomes for patients, and whether it affects the rate of adverse drug reactions — the harmful side effects that often accompany chemotherapy.
A systematic review is not a single experiment. It is a structured survey that gathers and weighs the existing published studies on a topic, which makes it a useful snapshot of where the research currently stands rather than a one-off result.
The focus on adverse drug reactions is notable. Chemotherapy's toxicity is a major reason patients struggle through treatment, and any tool that could steer clinicians toward regimens that work while causing less harm would matter for quality of life as much as survival.
Beyond the title and its stated focus, the available source does not provide the review's specific findings, the number of studies it examined, or its conclusions.
Why it matters: if AI can reliably help match cancer patients to chemotherapy regimens that are both more effective and easier to tolerate, it could improve survival and reduce suffering — and this review signals that the medical research community is taking that possibility seriously.